Evenamide Hydrochloride

The sodium channel blocker market is expanding rapidly due to increasing prevalence of neuropathic pain and rising demand for selective treatments targeting Nav1.7 and Nav1.8 inhibitors.

Newron Pharmaceuticals has received regulatory approval for its ENIGMA-TRS Phase III program evaluating Evenamide as an add-on therapy for treatment-resistant schizophrenia, with patient recruitment beginning immediately.

DelveInsight's latest pipeline report reveals over 55 pharmaceutical companies actively developing 60+ innovative drug candidates for schizophrenia treatment, indicating significant industry investment in addressing this serious mental illness.

The schizophrenia market is expected to grow significantly, driven by the launch of novel therapies and increased diagnosis rates.

Newron Pharmaceuticals has partnered with Myung In Pharm for the development and commercialization of evenamide in South Korea, contributing to a Phase III trial.